Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business

Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet